A Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors AbbVie
- 02 Jan 2019 Planned End Date changed from 25 Oct 2020 to 22 Jan 2021.
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.
- 11 Sep 2018 Planned End Date changed from 20 Aug 2020 to 25 Oct 2020.